- •
Esophageal adenocarcinoma (EAC) is the solid malignancy with the fastest increasing incidence in the Western world over the last 3 decades.
- •
Barrett's esophagus (BE) is the only known precursor to EAC and the strongest risk factor for this type of esophageal cancer.
- •
Other risk factors for EAC include gastroesophageal reflux disease, obesity, smoking, and male sex.
- •
Endoscopic screening for BE has the potential to reduce the clinical impact of the changing epidemiology of EAC, but it is not
Screening and Risk Stratification for Barrett's Esophagus: How to Limit the Clinical Impact of the Increasing Incidence of Esophageal Adenocarcinoma
Section snippets
Key points
Epidemiology of esophageal adenocarcinoma
The epidemiology of esophageal adenocarcinoma (EAC) has changed dramatically over the past 50 years in the Western world. Surgical series reported before the 1980s showed that esophageal squamous cell carcinoma (ESCC), which arises from the native multilayered squamous epithelium, was the most common malignancy in the esophagus.1, 2, 3, 4 However, subsequent Western case series published 10 to 15 years later indicated that the EAC had become the most common esophageal malignancy, exceeding the
Risk factors for EAC
Table 1 lists the clinical and epidemiologic factors that have been studied in relation to the incidence of EAC.
Modification of Risk Factors
The epidemiologic trends of EAC in the Western world, discussed earlier, have raised concern about this disease amongst public health officials and as a result, there has been a call for clinical and research strategies to limit the impact of this disease.70, 71, 72 Because the modifiable risk factors implicated in the pathogenesis are still not completely understood73 and because compliance with healthy-living campaigns is poor, it is difficult to promote strategies to change the risk profile
Screening modalities
Table 2 provides a summary of the diagnostic modalities proposed for BE and EAC screening.
Markers of risk stratification in patients with BE
Once BE is diagnosed, either through screening or as a result of an investigation for upper GI symptoms, surveillance is generally recommended followed by intervention at the point at which HGD or EAC is detected.111 The recent evidence that the cancer risk in patients with BE is lower than previously believed24, 28, 58 has fueled long-standing arguments about whether this approach is justified.108, 112, 113, 114, 115 Most patients with BE never develop cancer, and a recent systematic review
Future perspective
- •
The economic implications of endoscopic screening within the general population demand the introduction of cheaper and less invasive tests for an early diagnosis of EAC at a presymptomatic stage and identification of patients at higher risk, such as patients with dysplastic or genetically unstable BE.
- •
Novel endoscopic therapies allow ablation of BE with preventive strategies. Although it is difficult to envisage a scenario in which every single patient with BE undergoes endoscopic therapy,
References (138)
- et al.
Chemoradiation therapy and resection for carcinoma of the esophagus: short-term results
Ann Thorac Surg
(1985) - et al.
Comparison of three techniques of esophagectomy within a residency training program
Ann Thorac Surg
(1994) - et al.
Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status
Ann Thorac Surg
(1998) - et al.
The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends
Ann Oncol
(2012) - et al.
Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
Gastroenterology
(1987) - et al.
Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia
Am J Gastroenterol
(2002) - et al.
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets
Am J Gastroenterol
(2000) - et al.
Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis
Clin Gastroenterol Hepatol
(2010) - et al.
Association of obesity with hiatal hernia and esophagitis
Am J Gastroenterol
(1999) - et al.
Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets
Cancer Epidemiol
(2011)
The metabolic syndrome: a high-risk state for cancer?
Am J Pathol
Carcinogenicity of alcoholic beverages
Lancet Oncol
A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk
Ann Oncol
Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers
Gastroenterology
Improving screening practices for Barrett's esophagus
Surg Oncol Clin North Am
Medication usage and the risk of neoplasia in patients with Barrett's esophagus
Clin Gastroenterol Hepatol
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis
Gastroenterology
Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?
Am J Gastroenterol
Surveillance and survival in Barrett's adenocarcinomas: a population-based study
Gastroenterology
Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans
Gastrointest Endosc
Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease
Clin Gastroenterol Hepatol
Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis
Gastrointest Endosc
Cost-effectiveness of screening a population with chronic gastroesophageal reflux
Gastrointest Endosc
Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia
Gastrointest Endosc
Screening for Barrett's esophagus in colonoscopy patients with and without heartburn
Gastroenterology
Prevalence of Barrett's esophagus in asymptomatic individuals
Gastroenterology
Screening for Barrett's esophagus in asymptomatic women
Gastrointest Endosc
Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review
Gastroenterology
American Gastroenterological Association technical review on the management of Barrett's esophagus
Gastroenterology
Unsedated transnasal endoscopy accurately detects Barrett's metaplasia and dysplasia
Gastrointest Endosc
Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus
Gastrointest Endosc
Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video)
Gastrointest Endosc
Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux
Gastrointest Endosc
Combined radiation and surgical treatment of carcinoma of the esophagus
Ann Surg
Primary adenocarcinoma of the esophagus
Cancer
Carcinoma of the esophagus: results of treatment
Ann Surg
A 15-year review of esophagectomy for carcinoma of the esophagus and cardia
Arch Surg
Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution
Arch Surg
A global assessment of the oesophageal adenocarcinoma epidemic
Gut
The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence
J Natl Cancer Inst
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries
Int J Epidemiol
Trends in incidence of oesophageal and stomach cancer subtypes in Europe
Eur J Gastroenterol Hepatol
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
N Engl J Med
Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma
Cancer
Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux
Aliment Pharmacol Ther
Barrett's oesophagus: an ideal model to study cancer genetics
Hum Genet
Acid, bile, and CDX: the ABCs of making Barrett's metaplasia
Am J Physiol Gastrointest Liver Physiol
The prevalence of Barrett's esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population
Dig Dis Sci
Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study
BMJ
Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?
Gut
Cited by (13)
Review: Surveillance of patients with Barrett oesophagus
2016, Best Practice and Research: Clinical GastroenterologyCitation Excerpt :The protein p53 is coded by the tumor suppressor gene PT53 that is often mutated in BE. Overexpression of a nonfunctional protein p53 can be used in the diagnosis of dysplasia, but is also correlated with a higher risk of progression in nondysplastic BE to neoplasia [11,72,73]. Di Pietro et al. studied the combination of AFI and molecular markers in the detection of dysplasia.
Screening for Barrett's esophagus
2015, GastroenterologyCitation Excerpt :The devices also include a data recorder, comprising a recorder belt and sensor array, and a workstation for processing and real-time interpretation of transmitted images.78–80 ECE has an advantage over standard endoscopy in that it can be administered without sedation and is generally better tolerated.81 In initial studies, the PillCam ESO detected BE with 97% sensitivity and 99% specificity.82
Epithelial Metaplastic, Polypoid, and Neoplastic Conditions of the Esophagus
2021, Gastrointestinal Pathology: Correlative Endoscopic and Histologic AssessmentConfocal laser endomicroscopy of the upper digestive tract: history of development and screening
2020, Pirogov Russian Journal of SurgeryWhich interval is most crucial to presentation and survival in gastroesophageal cancer: A systematic review
2017, Journal of Advanced Nursing